Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR1F | P30939 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757883 | 0.88 | PIK3CD (0.41) | PIK3CDKMOHTR1AHTR1BHTR1F | |
| SCHEMBL21810460 | 0.88 | HDAC8 (0.36) | PIK3CDKMOPDE1BPDE1CMAPT | |
| SCHEMBL31104405 | 0.85 | KMO (0.43) | PIK3CDKMOIRAK4FGFR1FGFR4 | |
| SCHEMBL16595822 | 0.85 | KMO (0.43) | PIK3CDKMOIRAK4FGFR1FGFR4 | |
| SCHEMBL19279630 | 0.85 | PIK3CD (0.55) | PIK3CDKMOPDE1BPDE1CPDE10A | |
| SCHEMBL2980987 | 0.83 | PIK3CD (0.41) | PIK3CDKMOIRAK4FGFR1FGFR4 | |
| SCHEMBL17677989 | 0.83 | PIK3CD (0.41) | PIK3CDKMOIRAK4FGFR1FGFR4 | |
| SCHEMBL19698021 | 0.81 | PIK3CD (0.41) | PIK3CDKMOIRAK4FGFR1FGFR4 | |
| SCHEMBL20116574 | 0.81 | PDE1B (0.40) | PIK3CDKMOPDE1BPDE1CHTR1A | |
| SCHEMBL19689422 | 0.80 | PIK3CD (0.43) | PIK3CDKMOIRAK4FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596051-B1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-04-27 | — | — | EP | disclosed |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2020-03-19 | — | — | US | disclosed |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | GPR119, GPR65, GPR88 | PIK3CD 3200/4885KMO 2243/4885IRAK4 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.